ARIXTRA PI PDF

PI Trade Names and Active Ingredients containing Arixtra. 1 Documents available. Need more information on a product? Search the Australian Register of. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 mg04 mL mgmL75 mg06 mL injection of Arixtra mg in young healthy subjects are provided in Table 1 below: . Arixtra mg once daily following hip fracture surgery, patients were.

Author: Malazil Akijar
Country: Nicaragua
Language: English (Spanish)
Genre: Video
Published (Last): 7 December 2004
Pages: 112
PDF File Size: 11.54 Mb
ePub File Size: 15.20 Mb
ISBN: 347-2-23510-456-2
Downloads: 3534
Price: Free* [*Free Regsitration Required]
Uploader: Kajizil

PDR Search

Moderate Due to the thrombocytopenic effects of chlorambucil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants. For DVT or PE prophylaxis following abdominal surgery in patients who are risk for thromboembolic complications.

According to the manufacturer, if oxandrolone therapy is initiated in a patient already receiving warfarin, the dose of warfarin may need to be decreased significantly to reduce the potential for excessive INR elevations and associated risk of serious bleeding events. Patients should be instructed to monitor for signs and symptoms of bleeding while taking venlafaxine concurrently with an anticoagulant medication and to promptly report any bleeding events to the practitioner.

Major Cod liver oil should be used only with caution and with frequent monitoring in patients on concurrent anticoagulants. Steps should be taken to avoid the risk of bleeding and hematoma formation following intramuscular injection.

Moderate Use caution when discontinuing eltrombopag in patients receiving anticoagulants e. Adequate renal function is required as fondaparinux is excreted primarily as the unchanged drug. Ginkgo, Ginkgo biloba is reported to inhibit platelet aggregation and several case reports describe bleeding complications with Ginkgo biloba, with or without concomitant drug therapy.

Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs.

Occurrences of major bleeding in patients fondaparinux for treatment of DVT and PE with normal renal function, mild renal impairment, moderate renal impairment, and severe renal impairment have been found to be 0. Adults weight 50 kg or more. Moderate Give the extended-release injectable suspension of naltrexone cautiously to patients taking anticoagulants. A clear association with fondaparinux and fetal adverse developmental outcomes has not been demonstrated with available data from published literature and postmarketing reports.

  CHARLES HAANEL SYSTEM KLUCZA UNIWERSALNEGO PDF

There is an additive risk of beeding. The risk of bleeding and recurrent thrombocytopenia is increased in patients receiving these drugs when eltrombopag is discontinued.

Bleeding, endocarditis, epidural anesthesia, GI bleeding, lumbar puncture, spinal anesthesia, stroke, surgery. Monitor clinical and laboratory response closely during concurrent use. Neutralization of factor Xa interrupts the blood coagulation cascade that leads to thrombin formation and thrombus development. An in vivo interaction study in humans demonstrated that a single 1 mg dose of anagrelide administered concomitantly with a single dose of aspirin mg was well tolerated; there was no effect on bleeding time, PT, or PTT.

Fondaparinux should be used cautiously in patients with a history of heparin-induced thrombocytopenia HIT. Coadministration of apixaban and other anticoagulants may increase the risk of bleeding. Major Discontinue enoxaparin before starting fondaparinux due to the increased bleeding risk, unless these agents are essential.

Risk factors include those undergoing surgery with general anesthesia lasting more than 45 minutes who are 1 afixtra than 60 years or 2 more than 40 years with at least 1 of the following: Theoretically, the risk of bleeding may be increased, but some studies that combined these agents oi not produce clinically significant bleeding events.

Monitor INR levels when venlafaxine is added to or discontinued from warfarin therapy. All steps to avoid hematoma formation are recommended. Agents which may lead to an increased incidence of bleeding in patients with thrombocytopenia include anticoagulants.

Sulfinpyrazone is also known to markedly aritxra the effect of warfarin. Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide: Fondaparinux is a copy of the antithrombin III binding area of heparin. Clinical practice guidelines suggest alternative anticoagulants, such as warfarin, unfractionated heparin, or low molecular weight heparin, rather than fondaparinux during breast-feeding. Moderate The safety of cilostazol has not been established with concomitant administration of anticoagulants.

Moderate Because gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase arixtea risk of peptic arixtrs or gastric hemorrhage including anticoagulants. Moderate An additive risk of bleeding may be seen in patients receiving platelet inhibitors e. Unlike coumarins or heparinoids, an antidote to reverse bleeding with fondaparinux is not available.

Clinical practice guidelines recommend low molecular weight heparin for the prevention and treatment of venous thromboembolism during pregnancy. Occurrence of major bleeds in clinical trials for fondaparinux prophylaxis in hip fracture, hip replacement, or knee replacement surgery was 1. Since ginkgo produces clinically-significant antiplatelet effects, it should be used cautiously in patients drugs that inhibit platelet aggregation or pose a risk for bleeding, such as anticoagulants.

  LPC2378 MANUAL PDF

Major Danazol raixtra decrease hepatic synthesis of procoagulant factors, increasing the possibility of bleeding when atixtra concurrently with anticoagulants. Consider discontinuation of anticoagulants in a patient taking inotersen with a platelet count of less than 50, per microliter. In those with severe bleeding events, patients were often taking drugs that cause thrombocytopenia or affect platelet function or coagulation.

Moderate Patients should be instructed to monitor for signs and symptoms of bleeding while taking vilazodone concurrently with anticoagulants and to promptly report any bleeding events to the practitioner.

Major Avoid concurrent use of betrixaban with fondaparinux due to the increased bleeding risk. Major Platelet aggregation may be impaired by desvenlafaxine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication in patients receiving anticoagulants.

However, because fish oil, omega-3 fatty acids inhibit platelet aggregation, caution is advised when fish oils are used concurrently with anticoagulants, platelet inhibitors, or thrombolytic agents.

Persons who are receiving anticoagulants should not take kava kava without first discussing use with their health care professional. Major Discontinue thrombin inhibitors before starting fondaparinux due to the increased bleeding risk, unless these agents are essential.

Inhibits factor Xa but not factor IIa thrombin.

Severe Coadministration of defibrotide with antithrombotic agents like anticoagulants is arixttra. Patients were followed on a twice-weekly basis for INR determinations and adverse reactions.

Arixtra (fondaparinux sodium) dose, indications, adverse effects, interactions from

Therapy should be continued for at least 5 days and until a therapeutic warfarin response is established INR 2. Major Discontinue dalteparin before starting fondaparinux due to the increased bleeding risk, unless these agents are essential.

Concomitant anticoagulants may increase the risk of hemorrhage. Moderate When used concurrently with anticoagulants, epoprostenol may increase the risk of bleeding.